Cardinal Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAH research report →
Range $265 – $321
Price Chart
About the company
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home.
- CEO
- Jason Hollar
- IPO
- 1983
- Employees
- 61,344
- HQ
- Dublin, OH, US
Get TickerSpark's AI analysis on CAH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $63.06B
- P/E
- 35.20
- Fwd P/E
- 21.08
- PEG
- 2.13
- P/S
- 0.24
- P/B
- -20.92
- EV/EBITDA
- 18.63
- Div Yield
- 0.75%
- Gross Margin
- 3.90%
- Op Margin
- 1.05%
- Net Margin
- 0.71%
- ROE
- -62.56%
- ROIC
- 14.26%
Latest fiscal year · YoY change
- Revenue
- $254.25B+14.2%
- Gross Profit
- $9.77B+19.7%
- Op Income
- $2.61B
- Net Income
- $1.71B+9.8%
- EPS
- $7.27+12.2%
- OCF Growth
- +115.9%
- FCF Growth
- +144.6%
- 52W High
- $286.29
- 52W Low
- $180.45
- 50D MA
- $247.19
- 200D MA
- $226.38
- Beta
- 0.52
- RSI (14)
- 61
- Avg Volume
- 1.71M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cardinal Health started fiscal 2027 with broad-based growth, a record operating income quarter, and higher full-year EPS, pharma, and other-business guidance.· November 5, 2026
- Revenue rose 5% to $67.5 billion, gross profit increased 12% to $2.6 billion, and diluted EPS grew 28% to $3.26.
- Operating income reached $1 billion for the first time in a quarter, with gross profit outpacing SG&A growth.
- Pharma revenue grew 6% to $62.6 billion and segment profit rose 17% to $783 million, helped by specialty growth, generics, and stable core distribution.
- The ‘other’ businesses grew revenue 7% to $1.8 billion and profit 16% to $193 million, while GMPD profit came in at $33 million, above expectations.
- Management raised fiscal 2027 EPS guidance to $12.80-$13.00 and increased guidance for pharma and other, while keeping GMPD revenue guidance unchanged but noting profit is trending toward the low end.
Consolidated first-quarter revenue was $67.5 billion, up 5% year over year. Gross profit was $2.6 billion, up 12%, SG&A was $1.6 billion, up 9%, operating income was $1 billion, up 17%, and diluted EPS was $3.26, up 28%. Interest and other was $67 million and the effective tax rate was 18.5%. Pharma revenue was $62.6 billion, up 6%, with segment profit of $783 million, up 17%. GMPD revenue was roughly flat at $3.2 billion with segment profit of $33 million. Other revenue was $1.8 billion, up 7%, with profit of $193 million, up 16%. Cash at quarter-end was $5.3 billion after $1.6 billion of adjusted free cash flow. The company raised fiscal 2027 non-GAAP EPS guidance to $12.80-$13.00 from $12.40-$12.60. Pharma revenue guidance remains 3%-5%, while segment profit growth guidance rose to 10%-12% from 8%-11%. For GMPD, revenue guidance remains 2%-4% and profit is still guided to $200 million-$220 million, though management said it is tracking toward the low end due to high petroleum costs. For other, revenue guidance rose to 12%-14% from 11%-13% and profit guidance to 17%-20% from 15%-18%. The company kept interest and other guidance at $240 million-$290 million, lowered the tax-rate guide to 18.5%-19.5%, kept capex at about $700 million, expects diluted shares of 231 million-232 million, and still expects adjusted free cash flow of $3.5 billion-$4 billion.
Jason Hollar struck an upbeat, confident tone, saying the quarter showed a strong start to fiscal 2027 with broad-based growth and disciplined execution. He emphasized the durability of the core distribution business, the importance of the CVS renewal through June 2032, and continued progress in specialty, GMPD, and the growth businesses. He also framed policy risk as manageable and said the company’s priorities remain access, lower cost, and innovation.
Aaron Alt highlighted a strong quarter both above and below the line and tied the raised outlook to broad-based operating momentum. He cited 5% revenue growth to $67.5 billion, 12% gross profit growth to $2.6 billion, 17% operating income growth to $1 billion, and 28% EPS growth to $3.26, plus $1.6 billion of adjusted free cash flow and $5.3 billion of cash. He also noted the $500 million accelerated share repurchase completed in the quarter, capital investment of $157 million, dividends of about $125 million, and that leverage finished near the midpoint of the target range with investment-grade ratings preserved. On guidance, he raised EPS to $12.80-$13.00, lifted pharma and other profit expectations, kept GMPD revenue unchanged, and said higher petroleum costs are pressuring GMPD profit toward the low end of its range.
Analysts focused on the strength in pharma and specialty, the drivers of ‘other’ businesses, the impact of the OPPS/340B reimbursement changes, the outlook for Red Oak and generics, and future M&A. Management said pharma strength came from specialty, generics, and customer demand, with specialty running in the high teens and generics slightly above long-term targets. On 340B, Jason Hollar said the company expects volume to shift if providers find care less affordable, but it is too early to quantify the impact; he also said any provider-level effects should be second-order for Cardinal because of its diversified exposure. On Red Oak, management said the relationship continues to create value and could extend beyond 2029, with 2027 LOE benefits roughly consistent with last year but more benefit expected from 2029 onward.
The call showed momentum across multiple businesses, with pharma, specialty, and the growth businesses all outperforming and management raising full-year guidance. The CVS renewal through 2032, ongoing customer wins, and strong cash generation give the company visibility and flexibility to keep investing, repurchase shares, and pursue targeted M&A. Management also sounded confident that secular tailwinds in specialty, home care, and radiopharma can keep supporting growth.
GMPD remains the weak spot, with management saying high petroleum costs are pushing segment profit toward the low end of the annual range and that performance remains dependent on continued operational improvement. The company also flagged timing-related earnings moderation in the middle of the year from renewals and the Solaris lap, plus uncertainty around the practical impact of 340B and other reimbursement changes. While management is optimistic on M&A and integration, they acknowledged that some businesses are still in the early stages of realizing synergies and scaling.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 231.14M
- Float Shares
- 230.68M
of shares held by institutions
1,554 13F filers
Buy/sell ratio 0.41. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CAH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Oct 24, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | May 14, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Apr 8, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | May 5, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Mar 17, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Jan 21, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Sep 20, 24 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | May 2, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Jun 3, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 13, 24 | Filing → |
| Jonathan JacksonHouse · IL01 | Buy | Jan 12, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 31.44M | ▲ 617.77K |
| Blackrock, Inc. | 25.57M | ▼ 918.88K |
| Vanguard Capital Management LLC | 15.22M | ▼ 72.39K |
| Wellington Management Group Llp | 14.86M | ▲ 10.58M |
| Vanguard Portfolio Management LLC | 13.54M | ▼ 173.69K |
| State Street Corp | 12.05M | ▲ 82.55K |
| Geode Capital Management, LLC | 6.45M | ▼ 18.30K |
| Morgan Stanley | 5.10M | ▲ 472.10K |
| Invesco Ltd. | 4.60M | ▼ 139.35K |
| Norges Bank | 3.73M | ▲ 3.73M |
| Jpmorgan Chase & Co | 3.18M | ▲ 512.74K |
| Bank Of America Corp | 2.90M | ▲ 18.83K |
Held by 2,199 ETFs
Biggest fund positions in CAH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Ramakrishna Sudhakar | other | 755 |
| Nov 12, 26 | Musslewhite Robert W | other | 755 |
| Nov 12, 26 | MUNDKUR CHRISTINE | other | 755 |
| Nov 12, 26 | Killefer Nancy | other | 755 |
| Nov 12, 26 | JOHRI AKHIL | other | 1 |
| Nov 12, 26 | Hall Patricia Hemingway | other | 1,204 |
| Nov 12, 26 | Evans David C | other | 755 |
| Nov 6, 26 | Zielinski Anita A | other | 0 |
| Nov 12, 26 | Edison Sheri H. | other | 755 |
| Nov 12, 26 | Brennan Michelle | other | 755 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CAH coverage
Recent articles, reports, and earnings notes.
No research on CAH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CAH report →5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
247wallst.com · Nov 20
Jim Cramer Says Cardinal Health Is “the Stock That Is Made for This Moment”
247wallst.com · Nov 20
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
4 High-Yield Healthcare Stocks Retirees Should Buy for December Income
247wallst.com · Nov 18
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
zacks.com · Nov 17
Banco Santander S.A. Purchases 12,420 Shares of Cardinal Health, Inc. $CAH
defenseworld.net · Nov 17
5 Dividend Growth Stocks to Buy as NVDA CEO Resignation Rattles Market
zacks.com · Nov 16
Cardinal Health (CAH) is a Top-Ranked Growth Stock: Should You Buy?
zacks.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.